--Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating-March 2024-www.financetom.com

--Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating

May 2, 2024 6:09 AM

08:47 AM EDT, 05/02/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Previous page： Market Chatter: TKO Group's UFC Eyes Over $1 Billion a Year From Next TV Rights Deal Next page： Paramount Global Faces TV Media Pressures in 2025, UBS Says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: TKO Group's UFC Eyes Over $1 Billion a Year From Next TV Rights Deal

Jan 10, 2025

02:53 PM EST, 01/10/2025 (MT Newswires) -- TKO Group-owned (TKO) Ultimate Fighting Championship is aiming to secure more than $1 billion a year from its next media rights deal with Walt Disney's ( DIS ) ESPN, Bloomberg reported Friday. UFC and ESPN will enter an exclusive negotiation period later this month as their current deal expires at the end of...

Paramount Global Faces TV Media Pressures in 2025, UBS Says

Jan 10, 2025

02:48 PM EST, 01/10/2025 (MT Newswires) -- Paramount Global's ( PARAA ) Q4 revenue growth will stand at 6%, but a reversal of cyclical tailwinds from political advertising and the Super Bowl, along with sustained pressures in TV media will impact 2025 results, UBS said in a note Friday. We estimate TV advertising will decline high single digits year-over-year on...

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Jan 10, 2025

02:37 PM EST, 01/10/2025 (MT Newswires) -- Arvinas ( ARVN ) shares fell 5.7% in recent Friday trading after the company outlined plans for a data update on a breast cancer drug in collaboration with Pfizer ( PFE ) . Topline data from the monotherapy phase 3 VERITAC-2 trial of vepdegestrant is anticipated in Q1 for patients with estrogen receptor-positive...

Jan 10, 2025

...